Sidduri Achyutharao, Budd David C, Fuentes Maria E, Lambros Ted, Ren Yonglin, Roongta Vikram, Schoenfeld Ryan C, Gillespie Paul, Stevenson Christopher S, Truitt Theresa, Qian Yimin
Discovery Chemistry, Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.
Inflammation Discovery and Translational Area, Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4450-4454. doi: 10.1016/j.bmcl.2014.08.001. Epub 2014 Aug 8.
High throughput screening (HTS) of our chemical library identified 3-alkylamino-2-aryl-5H-imidazo[1,2,b]pyrazol-7-carbonitrile 1 as a potent antagonist of the LPA1 receptor (LPA1R). Further evaluation of this class of compounds indicated that LPA1R antagonist activity originated from the degradation of the parent molecule in DMSO during the assay conditions. Here, we describe the isolation and characterization of the degradation products and their LPA1R antagonist activity. We further profiled these novel non-carboxylic acid LPA1R antagonists and demonstrated their inhibition of LPA-induced proliferation and contraction of normal human lung fibroblasts (NHLF).
对我们的化学文库进行高通量筛选(HTS)后,确定3-烷基氨基-2-芳基-5H-咪唑并[1,2,b]吡唑-7-腈1是溶血磷脂酸1型受体(LPA1R)的有效拮抗剂。对这类化合物的进一步评估表明,LPA1R拮抗剂活性源于在测定条件下母体分子在二甲基亚砜(DMSO)中的降解。在此,我们描述了降解产物的分离与表征及其LPA1R拮抗剂活性。我们进一步分析了这些新型非羧酸LPA1R拮抗剂,并证明它们能抑制溶血磷脂酸(LPA)诱导的正常人肺成纤维细胞(NHLF)增殖和收缩。